Davide Benedetto Tiz got his diploma in 2014 in Chemistry and pharmaceutical technology at the University of Trieste (Italy) with the thesis "Synthesis and characterization of novel CK-1 inhibitors" under the supervision of Assoc. Prof. Stephanie Federico. He later completed his PhD at the faculty of Pharmacy, University of Ljubljana (Slovenia) in 2019 under the supervision of ‪Assoc. Prof. Nace Zidar, working on the design and synthesis of antibacterial compounds. His thesis "Discovery of novel N-phenylpyrrolamides as inhibitors of DNA gyrase and topoisomerase IV" was awarded by pharmaceutical company KRKA (Novo Mesto). While finishing his PhD he spent five months on ENABLE IMI project synthesising compounds with promising antibacterial activities. After finishing his PhD he worked at Fidelta, Zagreb (Croatia) as a medicinal chemist. He later conducted a Postdoctoral research at the University of Pardubice (Czech republic) under the supervision of Assoc. Prof. Dr. Aleš Imramovský. This basic research was focused to prepare new compounds (salicylamide – peptide aldehydes, various epoxides or boronic acids) which should join a large group of proteasome inhibitors. In 2022 he worked as a PostDoc fellow at University of Perugia, Italy. Since 2023 he has worked at National Institute of Chemistry, Ljubljana (Slovenia). 01/2024 Researcher at University of Ljubljana, Faculty of Chemistry Immobilized Catalysts for Deuteration ("ImCatD"), we propose to develop and evaluate new immobilized (bio)catalysts to be employed in continuous flow reactor systems (CFRS). Publication list: (1) Benedetto Tiz, D.; Bagnoli, L.; Rosati, O.; Marini, F.; Sancineto, L.; Santi, C. Top Selling (2026) Small Molecule Orphan Drugs: A Journey into Their Chemistry. International Journal of Molecular Sciences 2023, 24 (2), 930. (2) Tiz, D. B. Sintesi e Caratterizzazione Di Nuovi Inibitori Di CK-1: Tesi Sperimentale in Chimica Farmaceutica. 2014. (3) Tiz, D. B. Razvoj Novih N-Fenilpirolamidov Kot Zaviralcev DNA-Giraze in Topoizomeraze IV. 2019. (4) Cotman, A. E.; Guérin, T.; Kovačević, I.; Benedetto Tiz, D.; Durcik, M.; Fulgheri, F.; Možina, Š.; Secci, D.; Sterle, M.; Ilaš, J. Practical Synthesis and Application of Halogen-Doped Pyrrole Building Blocks. ACS omega 2021, 6 (14), 9723–9730. (5) Benedetto Tiz, D.; Kikelj, D.; Zidar, N. Overcoming Problems of Poor Drug Penetration into Bacteria: Challenges and Strategies for Medicinal Chemists. Expert Opinion on Drug Discovery 2018, 13 (6), 497–507. (6) Durcik, M.; Lovison, D.; Skok, Ž.; Cruz, C. D.; Tammela, P.; Tomašič, T.; Tiz, D. B.; Draskovits, G.; Nyerges, Á.; Pál, C. New N-Phenylpyrrolamide DNA Gyrase B Inhibitors: Optimization of Efficacy and Antibacterial Activity. European journal of medicinal chemistry 2018, 154, 117–132. (7) Benedetto Tiz, D.; Bagnoli, L.; Rosati, O.; Marini, F.; Sancineto, L.; Santi, C. New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. Molecules 2022, 27 (5), 1643. (8) Tiz, D. B.; Vicente, F. A.; Kroflič, A.; Likozar, B. Lignin-Based Covalent Adaptable Network Polymers─ When Bio-Based Thermosets Meet Recyclable by Design. ACS Sustainable Chemistry & Engineering 2023, 11 (38), 13836–13867. (9) Benedetto Tiz, D.; Podlipnik, C. Illicit Street Drugs?! Recent Trends and Chemistry. Recent Trends and Chemistry. Clin Case Rep Int. 2023; 7 2023, 1570. (10) Benedetto Tiz, D.; Bagnoli, L.; Rosati, O.; Marini, F.; Santi, C.; Sancineto, L. FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. Pharmaceutics 2022, 14 (11), 2538. (11) Cotman, A. E.; Durcik, M.; Benedetto Tiz, D.; Fulgheri, F.; Secci, D.; Sterle, M.; Mozina, S.; Skok, Z.; Zidar, N.; Zega, A. Discovery and Hit-to-Lead Optimization of Benzothiazole Scaffold-Based DNA Gyrase Inhibitors with Potent Activity against Acinetobacter Baumannii and Pseudomonas Aeruginosa. Journal of medicinal chemistry 2023, 66 (2), 1380–1425. (12) Grieco, I.; Bissaro, M.; Tiz, D. B.; Perez, D. I.; Perez, C.; Martinez, A.; Redenti, S.; Mariotto, E.; Bortolozzi, R.; Viola, G. Developing Novel Classes of Protein Kinase CK1δ Inhibitors by Fusing [1, 2, 4] Triazole with Different Bicyclic Heteroaromatic Systems. European Journal of Medicinal Chemistry 2021, 216, 113331. (13) Žula, M.; Grilc, M.; Kostyniuk, A.; Tofani, G.; Jasiukaitytė-Grojzdek, E.; Kozmelj, T. R.; Chowdari, R. K.; Lavrič, Ž.; Teržan, J.; Hočevar, B. Biorefining Twin Transition: Digitalisation for Bio-Based Chemicals/Materials-Discovery, Design and Optimisation. Chimia 2023, 77 (12), 816–826. (14) Tiz, D. B.; Skok, Ž.; Durcik, M.; Tomašič, T.; Mašič, L. P.; Ilaš, J.; Zega, A.; Draskovits, G.; Révész, T.; Nyerges, Á. An Optimised Series of Substituted N-Phenylpyrrolamides as DNA Gyrase B Inhibitors. European journal of m